Phase III data show Dupixent reduced itch in chronic spontaneous urticaria patients

Results from a Phase III trial have revealed that adding Dupixent (dupilumab) to standard-of-care antihistamines significanty reduced itch and hives at 24 weeks in biologic-naïve patients with chronic spontaneous urticaria (CSU), compared to antihistamines alone.

Data presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting demonstrated that patients who added Dupixent to standard-of-care antihistamines nearly doubled the reduction in itch and urticaria activity, compared to standard-of-care alone, with continuous improvement out to 24 weeks.

These patients experienced a 63% reduction in itch severity with Dupixent versus 35% with placebo. There was also a 65% reduction in urticaria activity (itch and hive) severity with Dupixent versus 37% with placebo.

CSU is a chronic inflammatory skin disease, characterised by the sudden onset of hives on the skin, and/or swelling deep underneath the skin. People with CSU often experience painful symptoms including a persistent itch or burning sensation, which is debilitating and can significantly impact quality of life. Whilst CSU can be treated with antihistamines, the disease is still uncontrolled for up to 50% of patients who have limited available treatment options.

Marcus Maurer, MD, Professor of Dermatological Allergology, Clinic for Dermatology, Venerology and Allergology at the Charité University of Medicine in Berlin, Germany, shared: “Despite standard-of-care antihistamines, many patients with chronic spontaneous urticaria continue to struggle with extreme itch, burning and pain associated with hives and swelling under the skin, which can significantly disrupt their daily lives. These encouraging results showed that, in those unable to achieve disease control on antihistamines alone, patients who added dupilumab experienced improved signs and symptoms and better control of their disease.”

Lina Adams